MicroRNA‑203a‑3p improves bleomycin and pingyangmycin sensitivity by inactivating the PI3K/AKT pathway in hemangioma

Zhuo,Lei; Hu,Zhenfeng; Chang,Jin; Guo,Qing; Guo,Jing

doi:10.3892/etm.2024.12369

MicroRNA‑203a‑3p improves bleomycin and pingyangmycin sensitivity by inactivating the PI3K/AKT pathway in hemangioma

Authors:
- Lei Zhuo
- Zhenfeng Hu
- Jin Chang
- Qing Guo
- Jing Guo
View Affiliations

Affiliations: Department of General Surgery IV (Department of Plastic Surgery), Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056002, P.R. China, Department of General Surgery II (Department of Plastic Surgery), Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056002, P.R. China, The Fourth Wards of Department of Oncology, Handan Central Hospital, Handan, Hebei 056001, P.R. China, The Fourth Wards of Department of Cardiovascular Medicine, Handan Central Hospital, Handan, Hebei 056001, P.R. China
Published online on: January 4, 2024 https://doi.org/10.3892/etm.2024.12369
Article Number: 80
Copyright: © Zhuo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) have been found to play a fundamental role in the pathology and progression of hemangioma. Of note, miR‑203a‑3p prevents hemangioma progression via inactivation of the PI3K/AKT pathway. Bleomycin and pingyangmycin are drugs used in sclerotherapy, but certain hemangioma patients experience drug resistance, leading to poor clinical outcomes. The present study aimed to explore the impact of miR‑203a‑3p on bleomycin and pingyangmycin sensitivity in hemangioma, as well as the involvement of the PI3K/AKT pathway. miR‑203a‑3p or negative control mimics were transfected into human hemangioma endothelial cells, which were treated with 0‑20 µM bleomycin or pingyangmycin. Subsequently, 740 Y‑P, a PI3K/AKT pathway agonist, was added. Cell viability, rate of apoptosis and the expression levels of proteins involved in the PI3K/AKT pathway, including phosphorylated (p)‑PI3K, PI3K, p‑AKT and AKT, were detected. miR‑203a‑3p overexpression significantly decreased the half‑maximal inhibitory concentration (IC50) values of bleomycin (5.84±0.87 vs. 14.23±2.17 µM; P<0.01) and pingyangmycin (5.13±0.55 vs. 12.04±1.86 µM; P<0.01), compared with untreated cells. In addition, under bleomycin or pingyangmycin treatment, miR‑203a‑3p overexpression significantly reduced the proportion of EdU positive cells (both P<0.05) and B‑cell leukemia/lymphoma‑2 (BCL2) protein expression levels (both P<0.05), whilst increasing cell apoptosis rate (both P<0.05) and cleaved caspase 3 protein expression levels (both P<0.05) compared with untreated controls. Furthermore, miR‑203a‑3p overexpression significantly inhibited the phosphorylation of PI3K and AKT (both P<0.05), an effect that was significantly diminished by 740 Y‑P treatment (both P<0.01). In addition, 740 Y‑P significantly increased IC50 values of bleomycin (P<0.01) and pingyangmycin (P<0.001) and also significantly increased the proportion of EdU‑positive cells and BCL2 protein expression levels, while decreasing the apoptosis rate and cleaved caspase 3 protein expression levels in cells treated with bleomycin or pingyangmycin (all P<0.05). Of note, 740 Y‑P weakened the effect of miR‑203a‑3p overexpression on the aforementioned cellular characteristics. The present study demonstrated that miR‑203a‑3p improved the sensitivity of cells to bleomycin and pingyangmycin treatment by inhibiting PI3K/AKT signaling in hemangioma.

View Figures

View References

1	Rodriguez Bandera AI, Sebaratnam DF, Wargon O and Wong LF: Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 85:1379–1392. 2021.PubMed/NCBI View Article : Google Scholar
2	Lin PF, Chen FC, Chen JY, Hu LH, Xie WJ, Liu TY, Guo SB, Lin XM, Liu XW, Ye XH, et al: Incidence and familial clustering of infantile haemangiomas: A multicentre study. J Eur Acad Dermatol Venereol. 36:1641–1647. 2022.PubMed/NCBI View Article : Google Scholar
3	Anderson KR, Schoch JJ, Lohse CM, Hand JL, Davis DM and Tollefson MM: Increasing incidence of infantile hemangiomas (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight. J Am Acad Dermatol. 74:120–126. 2016.PubMed/NCBI View Article : Google Scholar
4	Seiffert A, Schneider M, Roessler J, Larisch K and Pfeiffer D: Incidence, treatment patterns, and health care costs of infantile hemangioma: Results of a retrospective german database analysis. Pediatr Dermatol. 34:450–457. 2017.PubMed/NCBI View Article : Google Scholar
5	Leaute-Labreze C, Harper JI and Hoeger PH: Infantile haemangioma. Lancet. 390:85–94. 2017.PubMed/NCBI View Article : Google Scholar
6	Sebaratnam DF, Rodriguez Bandera AL, Wong LF and Wargon O: Infantile hemangioma. Part 2: Management. J Am Acad Dermatol. 85:1395–1404. 2021.PubMed/NCBI View Article : Google Scholar
7	Lee JC, Modiri O, England RW, Shawber CJ and Wu JK: Propranolol therapy in infantile hemangioma: It is not just about the beta. Plast Reconstr Surg. 147:875–885. 2021.PubMed/NCBI View Article : Google Scholar
8	Colmant C and Powell J: Medical management of infantile hemangiomas: An update. Paediatr Drugs. 24:29–43. 2022.PubMed/NCBI View Article : Google Scholar
9	Wang C, Sun J, Guo L, Song D, Zhang X, Liu Z and Wang L: Low-dose sclerotherapy with lauromacrogol in the treatment of infantile hemangiomas: A retrospective analysis of 368 cases. Front Oncol. 12(1014465)2022.PubMed/NCBI View Article : Google Scholar
10	Hassan Y, Osman AK and Altyeb A: Noninvasive management of hemangioma and vascular malformation using intralesional bleomycin injection. Ann Plast Surg. 70:70–73. 2013.PubMed/NCBI View Article : Google Scholar
11	Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, Xiang B, Qiu T, Dai S, Jiang X, et al: Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 147:599–607. 2021.PubMed/NCBI View Article : Google Scholar
12	Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, Choe YS, Lee H, Cheon JE, Park JB, et al: Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: A randomized clinical trial. JAMA Dermatol. 153:529–536. 2017.PubMed/NCBI View Article : Google Scholar
13	Chen T, Gudipudi R, Nguyen SA, Carroll W and Clemmens C: Should propranolol remain the gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol. Ann Otol Rhinol Laryngol. 132:332–340. 2023.PubMed/NCBI View Article : Google Scholar
14	Wu HW, Wang X, Zhang L, Zheng JW, Liu C and Wang YA: Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol. 8(605)2018.PubMed/NCBI View Article : Google Scholar
15	McGahan JP and Goldman RE: Percutaneous sclerotherapy with bleomycin and ethiodized oil: A welcomed minimally invasive treatment for giant liver hemangiomas. Radiology. 301:472–473. 2021.PubMed/NCBI View Article : Google Scholar
16	Chen ZY, Wang QN, Zhu YH, Zhou LY, Xu T, He ZY and Yang Y: Progress in the treatment of infantile hemangioma. Ann Transl Med. 7(692)2019.PubMed/NCBI View Article : Google Scholar
17	Ayoobi Yazdi N, Mehrabinejad MM, Dashti H, Pourghorban R, Nassiri Toosi M and Rokni Yazdi H: Percutaneous Sclerotherapy with bleomycin and ethiodized oil: A promising treatment in symptomatic giant liver hemangioma. Radiology. 301:464–471. 2021.PubMed/NCBI View Article : Google Scholar
18	Tiwari P, Pandey V, Bera RN, Tiwary N, Mishra A and Sharma SP: Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip. J Stomatol Oral Maxillofac Surg. 123:e499–e505. 2022.PubMed/NCBI View Article : Google Scholar
19	Hou J, Wang M, Tang H, Wang Y and Huang H: Pingyangmycin sclerotherapy for infantile hemangiomas in oral and maxillofacial regions: an evaluation of 66 consecutive patients. Int J Oral Maxillofac Surg. 40:1246–1251. 2011.PubMed/NCBI View Article : Google Scholar
20	Zhang C, Liu P, Huang J, Liao Y, Pan C, Liu J, Du Q, Liu T, Shang C, Ooi S, et al: Circular RNA hsa_circ_0043280 inhibits cervical cancer tumor growth and metastasis via miR-203a-3p/PAQR3 axis. Cell Death Dis. 12(888)2021.PubMed/NCBI View Article : Google Scholar
21	Chen L, Gao H, Liang J, Qiao J, Duan J, Shi H, Zhen T, Li H, Zhang F, Zhu Z and Han A: miR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D. Am J Cancer Res. 8:2387–2401. 2018.PubMed/NCBI
22	Dai L, Zhang W, Wu X and Zhou S: MicroRNA-203a-3p may prevent the development of thyroid papillary carcinoma via repressing MAP3K1 and activating autophagy. J Clin Lab Anal. 36(e24470)2022.PubMed/NCBI View Article : Google Scholar
23	Hu Z, Liu X, Guo J, Zhuo L, Chen Y and Yuan H: Knockdown of lncRNA MEG8 inhibits cell proliferation and invasion, but promotes cell apoptosis in hemangioma, via miR-203-induced mediation of the Notch signaling pathway. Mol Med Rep. 24(872)2021.PubMed/NCBI View Article : Google Scholar
24	Hu Z, Zhuo L, Li Y, Duan D and Guo J: MicroRNA-203a-3p suppresses endothelial cell proliferation and invasion, and promotes apoptosis in hemangioma by inactivating the VEGF-mediated PI3K/AKT pathway. Exp Ther Med. 24(644)2022.PubMed/NCBI View Article : Google Scholar
25	Mabeta P and Pepper MS: Inhibition of hemangioma development in a syngeneic mouse model correlates with bcl-2 suppression and the inhibition of Akt kinase activity. Angiogenesis. 15:131–139. 2012.PubMed/NCBI View Article : Google Scholar
26	Peng LX, Zhao P, Zhao HS, Pan E, Yang BB and Li Q: Phosphoinositide 3-kinase/Akt pathway is involved in pingyangmycin-induced growth inhibition, apoptosis and reduction of invasive potential in EOMA mouse hemangioendothelioma cells. Mol Med Rep. 12:8275–8281. 2015.PubMed/NCBI View Article : Google Scholar
27	Zhou B, Li L, Qiu X, Wu J, Xu L and Shao W: Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease. Mol Med Rep. 22:1489–1497. 2020.PubMed/NCBI View Article : Google Scholar
28	Zhao N, Du L, Ma Y, Wang Y, Ma J and Fang Z: LncRNA NEAT1/microRNA-124 regulates cell viability, inflammation and fibrosis in high-glucose-treated mesangial cells. Exp Ther Med. 24(507)2022.PubMed/NCBI View Article : Google Scholar
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
30	Tian S, Lou L, Tian M, Lu G, Tian J and Chen X: MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. J Exp Clin Cancer Res. 39(143)2020.PubMed/NCBI View Article : Google Scholar
31	Lin F, Yang Y, Wei S, Huang X, Peng Z, Ke X, Zeng Z and Song Y: Hydrogen sulfide protects against high glucose-induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway. Drug Des Devel Ther. 14:621–633. 2020.PubMed/NCBI View Article : Google Scholar
32	Jin W, Chen L, Gao F, Yang M, Liu Y and Wang B: Down-regulation of miR-556-3p inhibits hemangioma cell proliferation and promotes apoptosis by targeting VEGFC. Cell Mol Biol (Noisy-le-grand). 66:204–207. 2020.PubMed/NCBI
33	Wu Y, Li H, Xie J, Wang F, Cao D and Lou Y: miR-139-5p affects cell proliferation, migration and adipogenesis by targeting insulin-like growth factor 1 receptor in hemangioma stem cells. Int J Mol Med. 45:569–577. 2020.PubMed/NCBI View Article : Google Scholar
34	Yuan X, Xu Y, Wei Z and Ding Q: CircAP2A2 acts as a ceRNA to participate in infantile hemangiomas progression by sponging miR-382-5p via regulating the expression of VEGFA. J Clin Lab Anal. 34(e23258)2020.PubMed/NCBI View Article : Google Scholar
35	Hu X, Bai S, Li L, Tian P, Wang S, Zhang N, Shen B, Du J and Liu S: MiR-200c-3p increased HDMEC proliferation through the notch signaling pathway. Exp Biol Med (Maywood). 246:897–905. 2021.PubMed/NCBI View Article : Google Scholar
36	Wu M, Chen Y, Feng L, Dai H, Fang S and Xu J: MiR-206 promotes extracellular matrix accumulation and relieves infantile hemangioma through targeted inhibition of DNMT3A. Cell Cycle. 20:978–992. 2021.PubMed/NCBI View Article : Google Scholar
37	Ma Q, Dai X, Lu W, Qu X, Liu N and Zhu C: Silencing long non-coding RNA MEG8 inhibits the proliferation and induces the ferroptosis of hemangioma endothelial cells by regulating miR-497-5p/NOTCH2 axis. Biochem Biophys Res Commun. 556:72–78. 2021.PubMed/NCBI View Article : Google Scholar
38	An N and Zheng B: MiR-203a-3p inhibits pancreatic cancer cell proliferation, EMT, and apoptosis by regulating SLUG. Technol Cancer Res Treat. 19(1533033819898729)2020.PubMed/NCBI View Article : Google Scholar
39	Martin M, Zhang J, Miao Y, He M, Kang J, Huang HY, Chou CH, Huang TS, Hong HC, Su SH, et al: Role of endothelial cells in pulmonary fibrosis via SREBP2 activation. JCI Insight. 6(e125635)2021.PubMed/NCBI View Article : Google Scholar
40	Udalov S, Dumitrascu R, Pullamsetti SS, Al-tamari HM, Weissmann N, Ghofrani HA, Guenther A, Voswinckel R, Seeger W, Grimminger F and Schermuly RT: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med. 10(26)2010.PubMed/NCBI View Article : Google Scholar
41	Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, Guo X and Zhang Y: LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol Biochem. 46:1275–1285. 2018.PubMed/NCBI View Article : Google Scholar
42	Shen M, Dong C, Ruan X, Yan W, Cao M, Pizzo D, Wu X, Yang L, Liu L, Ren X and Wang SE: Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2. Cancer Res. 79:3608–3621. 2019.PubMed/NCBI View Article : Google Scholar
43	Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dechecchi MC, Prandini P, Gambari R, et al: A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro Oncol. 23:264–276. 2021.PubMed/NCBI View Article : Google Scholar
44	Yang K, Qiu T, Zhou J, Gong X, Zhang X, Lan Y, Zhang Z and Ji Y: Blockage of glycolysis by targeting PFKFB3 suppresses the development of infantile hemangioma. J Transl Med. 21(85)2023.PubMed/NCBI View Article : Google Scholar
45	Zhao Y, Li D, Han Y, Wang H, Du R and Yan Z: The ester derivatives obtained by C-ring modification of podophyllotoxin-induced apoptosis and inhibited proliferation in hemangioma endothelial cells via downregulation of PI3K/Akt signaling pathway. Chem Biol Drug Des. 99:828–838. 2022.PubMed/NCBI View Article : Google Scholar
46	Zhang Y, Zheng Y and Zhu G: MiR-203a-3p targets PTEN to promote hepatocyte proliferation by regulating PI3K/Akt pathway in BRL-3A cells. Biosci Biotechnol Biochem. 84:725–733. 2020.PubMed/NCBI View Article : Google Scholar